Sitemap > Breaking Research > Metabolic & Hormonal Disorders
Displaying 451 - 500 of 3753 results
- Albumin activates ERK via EGF receptor in human renal epithelial cells.
- Insulin resistance in men with treated hypertension at increased risk for cardiovascular disease: results of a 3-year study.
- PPARgamma in endothelial cells influences high fat diet-induced hypertension.
- LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function.
- A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
- Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance.
- Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X.
- Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.
- Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
- Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.
- Dipeptidyl peptidase IV inhibitors derived from beta-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole, or pyrazole.
- Benzimidazoles as non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 3: Discovery of 1-(1H-benzimidazol-5-yl)-3-tert-butylurea derivatives.
- The IkappaB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells.
- A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
- The ATP-sensitive potassium channel blocker glibenclamide prevents renal ischemia/reperfusion injury in rats.
- Effects of NADPH oxidase inhibitor in diabetic nephropathy.
- Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
- Excess deaths associated with underweight, overweight, and obesity.
- Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial.
- Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.
- Activation of hypothalamic ATP-sensitive K+ channels by the aminoguanidine carboxylate BVT.12777.
- Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
- Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System.
- Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.
- In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis.
- Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy.
- An integral role for heme oxygenase-1 and carbon monoxide in maintaining peripheral tolerance by CD4+CD25+ regulatory T cells.
- Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity.
- Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis.
- Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.
- The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
- Interleukin-6 depletion selectively improves hepatic insulin action in obesity.
- Hypothalamic K(ATP) channels control hepatic glucose production.
- Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.
- Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia.
- Immunomodulatory activities of small host defense peptides.
- Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin.
- Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
- Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
- Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
- The effect of vitamin K2 on bone metabolism in aged female rats.
- Discovery of a beta-MSH-derived MC-4R selective agonist.
- Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
- Sensitization and translocation of TRPV1 by insulin and IGF-I.
- Establishment of robust functional assays for the characterization of neuropeptide Y (NPY) receptors: identification of 3-(5-benzoyl-thiazol-2-ylamino)-benzonitrile as selective NPY type 5 receptor antagonist.
- Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice.
- Factors predicting the development of metabolic syndrome and type II diabetes against a background of hypertension.
- The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
- Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally-administered orexins in diabetic neuropathic pain model rats.
- Selective PPARgamma modulators with improved pharmacological profiles.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 Next >